Tri Locum Partners LP: VERTEX PHARMACEUTICALS (VRTX): Quarterly 13F Position History
As of Q1 2026, Tri Locum Partners LP reported 129,314 shares of VERTEX PHARMACEUTICALS (VRTX), worth $57.7M and representing 8.1% of its 13F equity book. Quarter-over-quarter share count change: + 129,314 (re-initiated) . The position first appeared in Q2 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 129,314Shares Held (Latest Filing)
- $57.7MReported Market Value (Latest Filing)
- 8.1%Portfolio Weight (% of 13F Equity Book)
- +129,314Quarter-over-Quarter Share Change
- +$57.7MQuarter-over-Quarter Value Change
- 129,314Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 129,314 | +129,314 | — | $57.7M | 8.1% | $446.5 |
| Q4 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 35,598 | -100.0% | $0 | 0.0% | — |
| Q1 2024 | 35,598 | +35,598 | — | $14.9M | 5.2% | $418.0 |
| Q4 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2023 | 0 | 24,597 | -100.0% | $0 | 0.0% | — |
| Q2 2023 | 24,597 | — | — | $8.7M | 3.2% | $351.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a VRTX position in 13F-HR filings?
Tri Locum Partners LP first reported VERTEX PHARMACEUTICALS (VRTX) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in VRTX?
Between Q4 2025 and Q1 2026, Tri Locum Partners LP added 129,314 shares of VRTX (re-initiated), bringing the total reported position to 129,314 shares at a market value of $57.7M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in VRTX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.